Stockholm, October 15, 2021 – IRRAS, a global medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that it will be participating in-person at the Congress of Neurological Surgeons’ annual meeting (CNS 2021), in Austin, TX, on October 16-20, 2021, as well as the Neurocritical Care Society’s annual meeting (NCS 2021), in Chicago, IL, on October 26-29, 2021. In addition, at CNS 2021, clinical data regarding the use of its IRRAflow system in the treatment of intracerebral hemorrhage (ICH) and intraventricular hemorrhage (IVH) will be presented in a case series poster by Dr. Behnam Rezai Jahromi from Helsinki University Hospital.
Both the CNS and NCS annual meetings are well-respected global medical conferences that connect neurosurgeons, neurointensivists, and related healthcare professionals, and IRRAS will be well represented with its exhibitor booth, live product demonstrations, and the poster presentation.
The poster presentation, titled “Active CSF Exchange is Effective for IVH Treatment – Active Removal of Intracerebral Hemorrhage,” will be available for review, both in-person and virtually, for registered participants of CNS 2021 beginning on Monday, October 18.
“Having the opportunity to participate in person at both the Congress of Neurological Surgeons and Neurocritical Care Society annual meetings is an important next step in our company’s emergence from the COVID-19 pandemic,” said Will Martin, President and Chief Executive Officer of IRRAS. “We are excited to connect with our customers in person, and we welcome all attendees to visit our IRRAS booth to learn more about our cutting-edge technologies.”
Conference attendees are encouraged to visit IRRAS’ booth #957 at CNS and booth #406 at NCS to learn more about IRRAflow®, the world’s first and only active fluid exchange system, as well as the Hummingbird Neuromonitoring product line.
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
President and CEO
Director, Investor Relations
The information was released for public disclosure, through the agency of the contact person above, on October 15, 2021 at 08:30 (CET).